RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.

Summary

In this study, newly diagnosed non-elderly patients with Philadelphia chromosomal negative (PH-) B-ALL were enrolled and 1:1 randomised into Reduced-intensity chemotherapy followed by Blinatumomab cohort or hyperCVAD cohort as induction therapy. The clinical remission rate, MRD negative rate and treaty-related adverse reactions were evaluated.

Timeline

Start

2024-02-05

Primary completion

2025-12-31

Completion

2026-12-31

Drugs

Indications